Back to top

Image: Bigstock

5 Winning Stocks Backed by the Overlooked Trick of Rising P/E

Read MoreHide Full Article

Trying hands at bargain stocks that have a low price-to-earnings (P/E) ratio is a common practice. The perception is that the lower the P/E, the higher will be the value of the stock.

This inference is drawn on the simple logic that a stock’s current market price does not justify (is not equivalent to) its higher earnings and therefore has room to run.

But have you ever given it a thought that stocks with a rising P/E can also be worth buying? We’ll tell you why this often-overlooked approach may go a long way in cherry picking some solid stocks. 

The screener yields winning stocks like Eastside Distilling (EAST - Free Report) , LogicBio Therapeutics (LOGC - Free Report) , Seabridge Gold (SA - Free Report) , Suzano (SUZ - Free Report) and J Douglas Emmett (DEI - Free Report) .

Why Rising P/E a Valuable Tool?

Investors should note that stock price moves in tandem with earnings performance. If earnings come in stronger, the price of a stock shoots up. Solid quarterly earnings and the forward guidance boost earnings forecasts, leading to stronger demand for the stock and an uptrend in its price.

So, if the price is rising steadily, it means that investors are assured of the stock’s fundamental strength and expect some strong positives out of it. Suppose an investor wants to buy a stock with a P/E ratio of 30, it means that he is willing to shell out $30 for only $1 worth of earnings. This is because the investor expects earnings of the company to rise at a faster pace in the future on the back of strong fundamentals.

Also, studies have revealed that stocks have seen their P/E ratios jump over 100% from their breakout point in the cycle. So, if you can pick stocks early in their breakout cycle, you can end up seeing considerable gains.

The Winning Strategy

In order to shortlist stocks that are exhibiting an increasing P/E, we chose the following as our primary screening parameters.

EPS growth estimate for the current year is greater than or equal to last year’s actual growth

Percentage change in last year EPS should be greater than or equal to zero

(These two criteria point to flat earnings or a growth trend over the years.)

Percentage change in price over four weeks greater than the percentage change in price over 12 weeks

Percentage change in price over 12 weeks greater than percentage change in price over 24 weeks

(These two criteria show that price of the stock is increasing consistently over the said timeframes.)

Percentage price change for four weeks relative to the S&P 500 greater than the percentage price change for 12 weeks relative to the S&P 500

Percentage price change for 12 weeks relative to the S&P 500 greater than the percentage price change for 24 weeks relative to the S&P 500

(Here, the case for consistent price gains gets even stronger as it displays percentage price changes relative to the S&P 500.)

Percentage price change for 12 weeks is 20% higher than or equal to the percentage price change for 24 weeks, but it should not exceed 100%

(A 20% increase in the price of a stock from the breakout point gives cues of an impending uptrend. But a jump of over 100% indicates that there is limited scope for further upside and that the stock might be due for a reversal.)

In addition, we place a few other criteria that lead us to some likely outperformers.

Zacks Rank less than or equal to 2: Only companies with a Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy) can get through.

Average 20-day Volume greater than or equal to 50,000: High trading volume implies that the stocks have adequate liquidity.

Just these few criteria narrowed down the universe from over 7,700 stocks to just 29.

Here are five out of the 29 stocks:

Eastside Distilling (EAST - Free Report) : The Zacks Rank #2 companyis involved in producing handcrafted spirits primarily in the United States. You can see the complete list of today’s Zacks #1 Rank stocks here.

The average earnings surprise of EAST for the past four quarters is 25.82%.

LogicBio Therapeutics (LOGC - Free Report) : This Zacks Rank #2 company is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs.

The average earnings surprise of LOGC for the past four quarters is 12.08%.

Seabridge Gold (SA - Free Report) : Seabridge Gold is a global leader in gold and mining listings.It has a Zacks Rank #1.

The average earnings surprise of SA for the past four quarters is 87.86%.

Suzano (SUZ - Free Report) : Zacks Rank #2Suzano S.A. is a producer of eucalyptus pulp as well as paper.

The average earnings surprise of SUZ for the past four quarters is 46.71%.

Douglas Emmett (DEI - Free Report) :  The Zacks Rank #2 companyis a fully-integrated, self-administered and self-managed real estate investment trust (REIT), and one of the largest owners and operators of high-quality office and multifamily properties located in the premier coastal submarkets of Los Angeles and Honolulu.

The average earnings surprise of DEI for the past four quarters is 1.67%.

You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance.

Published in